ATE529400T1 - Weiche anticholinerge zwitterionen - Google Patents

Weiche anticholinerge zwitterionen

Info

Publication number
ATE529400T1
ATE529400T1 AT06837428T AT06837428T ATE529400T1 AT E529400 T1 ATE529400 T1 AT E529400T1 AT 06837428 T AT06837428 T AT 06837428T AT 06837428 T AT06837428 T AT 06837428T AT E529400 T1 ATE529400 T1 AT E529400T1
Authority
AT
Austria
Prior art keywords
soft anticholinergic
anticholinergic zwitterions
zwitterions
phenyl
chiral center
Prior art date
Application number
AT06837428T
Other languages
English (en)
Inventor
Nicholas S Bodor
Original Assignee
Nicholas S Bodor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas S Bodor filed Critical Nicholas S Bodor
Application granted granted Critical
Publication of ATE529400T1 publication Critical patent/ATE529400T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/08Mydriatics or cycloplegics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • C07D451/10Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06837428T 2005-11-10 2006-11-13 Weiche anticholinerge zwitterionen ATE529400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73520605P 2005-11-10 2005-11-10
PCT/US2006/043966 WO2007059021A1 (en) 2005-11-10 2006-11-13 Soft anticholinergic zwitterions

Publications (1)

Publication Number Publication Date
ATE529400T1 true ATE529400T1 (de) 2011-11-15

Family

ID=37845110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06837428T ATE529400T1 (de) 2005-11-10 2006-11-13 Weiche anticholinerge zwitterionen

Country Status (4)

Country Link
US (5) US7399861B2 (de)
EP (1) EP1957451B1 (de)
AT (1) ATE529400T1 (de)
WO (1) WO2007059021A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050231A1 (es) * 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
ES2617680T3 (es) 2009-04-09 2017-06-19 Novartis Ag Proceso para la preparación de sales de pirrolidinio
KR101317924B1 (ko) * 2011-05-17 2013-10-16 김동진 글리코피롤레이트의 합성방법 및 이 활성성분을 함유하는 약학적 조성물의 제조방법
CN103159659A (zh) * 2011-12-19 2013-06-19 沈阳药科大学 一种毒蕈碱受体拮抗剂格隆溴铵的制备方法
CN103012231B (zh) * 2012-12-14 2015-08-05 沈阳药科大学 格隆溴铵手性对映体的制备方法和应用
WO2014140318A1 (en) * 2013-03-14 2014-09-18 K.H.S. Pharma Holding Gmbh Improved process for acyl transfer reactions
WO2014144075A1 (en) 2013-03-15 2014-09-18 Bodor Laboratories, Inc. Anticholinergic glycopyrrolate esters for the treatment of hyperhidrosis
JP2017507959A (ja) 2014-03-13 2017-03-23 ボドール ラボラトリーズ, インコーポレイテッド 選択された抗コリン作動性両性イオンの使用
US20150259283A1 (en) 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US9381147B2 (en) 2014-10-20 2016-07-05 Johnson & Johnson Consumer Inc. Compositions comprising zwitterionic ester ammonioalkanoates
US9533951B2 (en) 2014-10-20 2017-01-03 Eastman Chemical Company Heterocyclic amphoteric compounds
US9943816B2 (en) 2014-10-20 2018-04-17 Eastman Chemical Company Amphoteric ester sulfonates
CN119033771A (zh) * 2015-07-21 2024-11-29 博多尔实验仪器公司 软性抗胆碱能药类似物的制剂
TWI654976B (zh) * 2015-09-10 2019-04-01 美商波德實驗股份有限公司 選定的抗膽素激導性兩性離子之用途
CA2998353A1 (en) * 2015-09-11 2017-03-16 Bodor Laboratories, Inc. Methods and compositions for soft anticholinergic zwitterions
MY197265A (en) 2015-09-11 2023-06-08 Bodor Laboratories Inc Methods and compositions for soft anticholinergic esters
US11414380B2 (en) 2015-09-17 2022-08-16 Eastman Chemical Company Amphoteric compounds
US9993408B2 (en) 2015-09-17 2018-06-12 Johnson & Johnson Consumer Inc. Compositions comprising zwitterionic alkyl-alkanoylamides and/or alkyl alkanoates
WO2017138588A1 (ja) * 2016-02-10 2017-08-17 住友化学株式会社 1-メチルピロリジン-3-オールの製造方法
WO2018006001A1 (en) * 2016-07-01 2018-01-04 Bodor Laboratories, Inc. Compositions and methods for treatment of copd
TWI767507B (zh) * 2016-07-21 2022-06-11 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
WO2018026869A1 (en) 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds
EP3972955A4 (de) * 2019-05-23 2023-07-05 Kaken Pharmaceutical Co., Ltd. Kristalline form von sofpironiumbromid und verfahren zu ihrer herstellung
WO2021113260A1 (en) 2019-12-02 2021-06-10 Dermira, Inc. Diester containing compounds for treating hyperhidrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7417147B2 (en) 2008-08-26
US20070123557A1 (en) 2007-05-31
US8071639B2 (en) 2011-12-06
US7399861B2 (en) 2008-07-15
US20120141401A1 (en) 2012-06-07
US20080242651A1 (en) 2008-10-02
EP1957451B1 (de) 2011-10-19
US8568699B2 (en) 2013-10-29
EP1957451A1 (de) 2008-08-20
US20090257969A1 (en) 2009-10-15
US7538219B2 (en) 2009-05-26
WO2007059021A1 (en) 2007-05-24
US20080027091A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE529400T1 (de) Weiche anticholinerge zwitterionen
FR23C1040I1 (fr) Combinaison comprenant un cristal stable d&#39;un composé 4-oxoquinoline
WO2007030582A3 (en) Acyclic ikur inhibitors
CR8986A (es) Isoxazoles sustituidos como fungicidas
CR9113A (es) Compuestos acetamida como fungicidas
IL185108A0 (en) Processes for preparing cinacalcet hydrochloride crystal form i
EP1736465A4 (de) Anilinderivative
BRPI0415449A (pt) combinações de compostos ativos fungicidas sinergìsticos
ECSP088119A (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida
CR10157A (es) Compuestos químicos
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
TW200605879A (en) Pyrrolidinyl derivatives as 11-β hydroxysteroid dehydrogenase inhibitors
EA200702670A1 (ru) Препарат тиенопиридинового ингибитора агрегации тромбоцитов
ATE529399T1 (de) Sanfte anticholinerge ester
CR9680A (es) Pesticidal mixtures
BRPI0515918A (pt) sais de composto heterocìclico de ligação à quimiocina e métodos para seu uso
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
IL190024A0 (en) Stabilized protease composition
ATE519818T1 (de) Reversibel thermochrome zusammensetzung
IL178032A0 (en) An improved process for the preparation of n-([1,2,4-]triazolopyrimidin-2-yl)aryl sulfonamides
EA200700766A1 (ru) Способ получения производных [1,4,5]-оксадиазепина
UY29746A1 (es) Mezclas pesticidas
CR9687A (es) Mezclas pesticidas
BRPI0512310A (pt) compostos quìmicos
ATE469647T1 (de) Thienoä3,2-cüpyridin-7-carbonsäure-derivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties